N Anthony Coles has sold stock and made no open-market buys since Sep 2018

N. Anthony (Tony) Coles, M.D., M.P.H. is an American physician and biotechnology executive who serves as chair of the board of directors of Cerevel Therapeutics Holdings, Inc., where he has been chair since 2018 and previously served as chief executive officer from 2019 to 2023.( As a corporate insider, he is also a director of Regeneron Pharmaceuticals, Inc. and has previously served on the boards of McKesson Corporation, CRISPR Therapeutics AG, Laboratory Corporation of America Holdings, and other life sciences and healthcare companies.(

Dr. Coles has held multiple chief executive roles across the biopharmaceutical industry, including president, CEO, and chair of Onyx Pharmaceuticals, where he led the company until its acquisition by Amgen, and president and CEO of NPS Pharmaceuticals.( He co‑founded and served as chair and CEO of Yumanity Therapeutics, a biotechnology company focused on neurodegenerative disease drug discovery, and is chair and CEO of the private company TRATE Enterprises.( Earlier in his career, he held senior leadership roles at Vertex Pharmaceuticals as senior vice president of commercial operations and held executive and increasing-responsibility positions at Bristol‑Myers Squibb and Merck.( Dr. Coles earned a bachelor’s degree from Johns Hopkins University, a medical degree from Duke University, and a master’s in public health from Harvard University, and completed cardiology and internal medicine training at Massachusetts General Hospital along with a research fellowship at Harvard Medical School.(

Written by Perplexity from public sources.